SuperworthCRISPR Therapeutics market cap CRSP
Share price times shares outstanding: what the whole company sells for, since 2016.
- Today, Oct 23, 2026
- $4.8B
- Highest close in our data
- $14.1B
- Jan 2021
CRISPR Therapeutics is worth $4.8B at the close on Oct 23, 2026, at $49.39 a share.
That is down 22% over the last year and down 31% over five years.
Its highest close in our data was $14.1B in Jan 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $4.8B | $4.4B | $5.8B | −9% |
| 2025 | $5.2B | $2.8B | $6.6B | +54% |
| 2024 | $3.4B | $3.4B | $6.7B | −31% |
| 2023 | $5B | $3.1B | $5.6B | +56% |
| 2022 | $3.2B | $3.2B | $6.5B | −45% |
| 2021 | $5.8B | $5.4B | $14.1B | −46% |
| 2020 | $10.8B | $2.3B | $11.9B | +197% |
| 2019 | $3.6B | $1.6B | $4B | +162% |
| 2018 | $1.4B | $1.1B | $3.3B | +44% |
| 2017 | $963.1M | $569.6M | $963.1M | +19% |
| 2016 | $806.5M | $757.6M | $830.4M | n/a |
Against its peers
Companies in Biotechnology nearest CRISPR Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| CRSPCRISPR Therapeutics | $4.8B |
| KRYSKrystal Biotech | $9.2B |
| ADMAAdma Biologics | $2.4B |
| RGENRepligen | $10B |
| VCELVericel | $2.2B |
| TECHBIO-TECHNE | $11.4B |
| HALOHalozyme Therapeutics | $14.3B |
| NBIXNeurocrine Biosciences | $14.5B |
| EXELExelixis | $16B |
| INCYIncyte | $23.5B |
| UTHRUnited Therapeutics | $25.2B |
| Peer median | $12.8B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on CRISPR Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.